Memorial Sloan Kettering Cancer Center
The Patent and Royalties Manager at Memorial Sloan Kettering Cancer Center plays a critical role in protecting, managing, and maximizing the value of intellectual property generated through scientific research. This position partners with researchers, legal professionals, and business stakeholders to support the lifecycle of patents, licenses, and royalty-related activities. The role involves overseeing complex patent and royalty administration processes, ensuring accuracy and compliance across intellectual property portfolios, and contributing to strategies that strengthen technology commercialization efforts.
Headquarters
New York, New York, United States
Company Size
10001+ employees
Founded
1884
Memorial Sloan Kettering Cancer Center is a leading New York cancer care, research, and education institution founded in 1884. It delivers comprehensive patient care for all cancer types and partners with the Sloan Kettering Institute to advance basic and translational cancer research, while offering extensive education and training programs for clinicians and scientists.
MSK Offers Second Opinions for Cancer Diagnosis: 9 Things Patients Should Know
Dec 18, 2025
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Sep 29, 2025
Insurer and cancer center reach agreement in contract dispute that left thousands of patients in limbo
Jul 1, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Memorial Sloan Kettering Cancer Center.
Memorial Sloan Kettering partners on AI to surface oncology clinical trials
Oct 27, 2025